PapersPMID:22797645
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 6 months
- Dose studied, every finding
- 420 mg or 700 mg silymarin three times daily for 24 weeks
No finding here moved its endpoint.
What did not
How to read these marks →“Furthermore, there was no statistically significant difference across treatment groups (P=.75) when changes in serum ALT levels from baseline to end of treatment were analyzed as a continuous variable (mean decline, −4.3 [95% CI, −17.3 to 8.7] U/L for placebo, −14.4 [95% CI, −41.6 to 12.7] U/L for 420-mg silymarin, and −11.3 [95% CI, −27.9 to 5.4] U/L for 700-mg silymarin).”
- Interests
- Industry funded
- Population
- Adults with chronic hepatitis C who had not responded to interferon-based therapy and had serum ALT of 65 U/L or greater; three-group comparison of silymarin 420 mg, silymarin 700 mg and placebo; change in ALT from baseline to end of treatment
“Comparing placebo vs silymarin (either dose), the proportion of patients with at least 1 serious adverse event in the silymarin groups (7/102) did not differ significantly from the proportion in the placebo group (1/52) (P =.27).”
- Interests
- Industry funded
- Population
- Adults with chronic hepatitis C who had not responded to interferon-based therapy; silymarin at either dose (420 mg or 700 mg three times daily, pooled) versus placebo
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults with chronic hepatitis C (ALT 65 U/L or greater) previously unsuccessfully treated with interferon-based therapy; SyNCH trial; silymarin as Legalon 140, a dry extract of milk thistle fruits (S marianum)
- Participants
- 154
- Comparator
- placebo
- Duration
- 168 days
- Endpoints measured
- 30